Non-small Cell Lung Cancer study: STX-241
Official title Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
ClinicalTrials.gov ID: NCT06567015
What this study is testing
What is STX-241?
STX-241 is an investigational oral tablet being studied as a potential treatment for non‑small cell lung cancer that has progressed after third‑generation EGFR inhibitors.
Also referred to as PFL-241.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study will look at how safe the drug is, find the best dose for later trials, and see how the drug behaves in the body and whether it can slow the cancer’s growth.
- Who it's for
- It is for adults with advanced non‑small cell lung cancer that has spread or grown after using a third‑generation EGFR drug like osimertinib and has a specific resistance mutation.
- What's involved
- Participants will receive the drug and have regular blood tests, scans, and clinic visits to monitor safety and drug levels.
- Time commitment
- The study lasts several months, with multiple clinic visits and tests scheduled throughout the treatment period.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Signed and dated informed consent for participation in the trial obtained according to International Council for Harmonisation of Technical...
- Male or female ≥ 18 years of age at the time of signing informed consent but at least of legal age in their country.
- Histological confirmation of locally advanced or metastatic, EGFR-mutant (ex19del or L858R mutations) non-small cell lung cancer (NSCLC) Stage IIIB/C...
- Part 1 Disease progression on a 3rd generation EGFR TKI-based therapy (administered as monotherapy or in combination) received at any prior line of...
- Part 1 (backfilling component): Presence of C797X and absence of T790M mutations documented locally (as part of clinical practice) on a sample (blood...
You likely can't join if
- Part 1: Participants candidate for targeted therapies available to them (such as but not limited to therapies targeting ALK, BRAF, MET, NTRK, ROS1)...
- Part 2: Participants who received 1st or 2nd generation EGFR TKIs.
- Participant with rapid progressive disease eligible to receive a platinum-based chemotherapy.
- Participant unable ingest or digest tablets. This can be caused by any impaired gastrointestinal function or disease, such as for example: ulcerative...
- Participants with a previous malignancy that completed all curative anticancer treatment at least 2 years before signing informed consent and with no...
- Malignancies with a negligible risk of metastasis or death (i.e. 5-year overall survival rate \> 90%) that are adequately treated - Examples include...
See the full eligibility criteria
Who can join
- Signed and dated informed consent for participation in the trial obtained according to International Council for Harmonisation of Technical Requirements of Pharmaceuticals for Human Use (ICH) Good Clinical Practice...
- Male or female ≥ 18 years of age at the time of signing informed consent but at least of legal age in their country.
- Histological confirmation of locally advanced or metastatic, EGFR-mutant (ex19del or L858R mutations) non-small cell lung cancer (NSCLC) Stage IIIB/C or IV (AJCC 8th edition) not eligible for curative intent surgery or...
- Part 1 Disease progression on a 3rd generation EGFR TKI-based therapy (administered as monotherapy or in combination) received at any prior line of treatment.
- Part 1 (backfilling component): Presence of C797X and absence of T790M mutations documented locally (as part of clinical practice) on a sample (blood or tissue) collected after progression on treatment with 3rd...
- Part 2: Presence of C79X mutation documented locally (as part of clinical practice) on a sample (blood or tissue) collected after progression on a 3rd generation EGFR TKI-based therapy.
- Part 1 (Backfilling component), Part 2: At least one measurable target lesion according to RECIST v1.1.
- Eastern cooperative oncology group (ECOG) performance status 0-1.
- Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L
- Platelets ≥ 75 x 10\^9/L
- Hemoglobin ≥ 90 g/L.
- Serum total bilirubin ≤ 1.5 x ULN or ≤ 3.0 × ULN for participants with documented Gilbert's syndrome.
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.0 x ULN. If the participant has liver metastases, AST and ALT ≤5 × ULN.
- Estimated glomerular filtration rate (GFR) ≥ 50 mL/min by CKD-EPI equation
- Mean QT interval corrected for heart rate according to Fridericia's formula (QTcF) value ≤ 470 msec for women and ≤ 450 msec for men and no history of long QT syndrome or risk factors for torsade de pointe.
- Left ventricular ejection fraction (LVEF) ≥ 50% .
- Systolic blood pressure \< 150 mmHg and diastolic blood pressure \< 100 mmHg
- Negative highly sensitive serum β-HCG test performed within 7 days prior to first dose of STX-241 (C1D1) and a negative urine pregnancy test performed prior to C1D1.
- Agreement to use one highly effective contraceptive method (as defined in protocol and according to local regulations), starting at screening period, throughout the trial and until at least 182 days (i.e.
- Agreement to not donate eggs (ova, oocytes) for the purpose of assisted reproduction during the trial and for a period of 182 days after the last dose of STX-241.
- Consistently use a barrier method [e.g., condom with spermicidal foam / gel / film /cream/suppository], and his female partner use a highly effective method of contraception as defined in protocol and according to local...
- Not donate sperm from Day 1 (first administration of STX-241) until at least 92 days after the last dose of STX-241. NOTE: Other protocol defined may apply.
What rules you out
- Part 1: Participants candidate for targeted therapies available to them (such as but not limited to therapies targeting ALK, BRAF, MET, NTRK, ROS1) as identified by local testing performed after progression to the last...
- Part 2: Participants who received 1st or 2nd generation EGFR TKIs.
- Participant with rapid progressive disease eligible to receive a platinum-based chemotherapy.
- Participant unable ingest or digest tablets. This can be caused by any impaired gastrointestinal function or disease, such as for example: ulcerative diseases, malabsorption syndrome, small bowel resection, ileus, etc.
- Participants with a previous malignancy that completed all curative anticancer treatment at least 2 years before signing informed consent and with no evidence of residual disease from the prior malignancy at screening.
- Malignancies with a negligible risk of metastasis or death (i.e. 5-year overall survival rate \> 90%) that are adequately treated - Examples include, but are not limited to, completely resected basal cell carcinoma and...
- Spinal cord compression or CNS metastases that are associated with progressive neurological symptoms or require increasing doses of corticosteroids to control the CNS disease.
- History of hypersensitivity to active or inactive ingredients of STX-241, or drugs with a similar chemical structure or from the same class.
- Active, bacterial, fungal, or viral infection, including, but not limited to: Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and known Human Immunodeficiency Virus (HIV) or Acquired Immunodeficiency Syndrome...
- Positive SARs-CoV-2 or variants of SARs-CoV2 RT-PCR test or suspected to be infected with SARs-CoV2 or variants of SARsCoV2 with confirmation pending within 2 weeks of first dose of STX-241.
- Myocardial infarction, acute coronary syndromes including unstable angina, coronary/peripheral artery bypass graft, coronary angioplasty or stenting.
- Symptomatic congestive heart failure (New York Heart Association Classification Class ≥ II).
- Cerebrovascular accident or transient ischemic attack.
- Symptomatic bradycardia, requirement for anti-arrhythmic medication.
- Ongoing cardiac dysrhythmia of NCI-CTCAE Grade ≥2.
- Uncontrolled intercurrent illness including, but not limited to ongoing or active infection or psychiatric illness/social situation that would limit compliance with trial requirements.
- Past medical history of Interstitial Lung Disease (ILD), drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD.
- Past medical history of Stevens-Jonhson Syndrome (SJS) or Toxic epidermal necrolysis (TEN) or any evidence of clinically active SJS/TEN.
- Women who are breast feeding.
- EGFR-targeted TKI within 7 days prior to the first dose of STX-241.
- Any other systemic anticancer therapy within 28 days or 5 half-lives prior to the first dose of STX-241, whichever is the shortest, but with a minimum of 14 days in all circumstances.
- Radiotherapy to a large field or including a vital organ (including whole brain radiotherapy or stereotactic radiosurgery to brain) within 14 days before the first dose of STX-241.
- Live attenuated vaccine received within 30 days prior to the first dose of STX-241.
- Any toxicities from prior therapy with a NCI-CTCAE Grade ≥1 at the time of the first dose of STX-241 (C1D1). Exceptions include alopecia (any grade), fatigue with a Grade ≤2, and peripheral neuropathy with a Grade ≤2.
- Major surgical procedure within 14 days of the first dose of STX-241 (procedures such as central venous catheter placement, tumor needle biopsy, and feeding tube placement are not considered major surgical procedures).
- At least 5 half-lives plus 14 days for strong CYP inducers.
- At least 5 half-lives for CYP inhibitors, CYP/transporter substrates, proton pump inhibitor (PPI) and H2 antagonists.
- Participation in a clinical trial with administration of an investigational drug within 5 half-lives plus 14 days of the investigational drug, before the first dose of STX-241.
- Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.
- Employee or family member of the investigator or site staff. NOTE: Other protocol defined exclusion criteria may apply.
The study team makes the final eligibility decision.
Where it is enrolling
- Nashville, Tennessee, United States
- Houston, Texas, United States
- Shanghai, China
- Tianjin, China
- Lyon, France
- Marseille, France
- Saint-Herblain, France
- Toulouse, France
- Villejuif, France
- Dresden, Germany
- Amsterdam, Netherlands
- Barcelona, Spain
- Logroño, Spain
- Madrid, Spain
- Taipei, Taiwan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Nashville, Tennessee, United States; Houston, Texas, United States; Shanghai, China; Tianjin, China; Lyon, France; Marseille, France and 9 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.